SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects

Melanie Galano¹, Shereen Ezzat² and Vassilios Papadopoulos¹*

Abstract

Background: The detoxification of very long-chain and branched-chain fatty acids and the metabolism of cholesterol to form bile acids occur largely through a process called peroxisomal β-oxidation. Mutations in several peroxisomal proteins involved in β-oxidation have been reported, resulting in diseases characterized by neurological defects. The final step of the peroxisomal β-oxidation pathway is catalyzed by sterol carrier protein-x (SCPx), which is encoded by the SCP2 gene. Previously, there have been two reports of SCPx deficiency, which resulted from a homozygous or compound heterozygous SCP2 mutation. We report herein the first patient with a heterozygous SCP2 mutation leading to SCPx deficiency.

Results: Clinical presentations of the patient included progressive brainstem neurodegeneration, cardiac dysrhythmia, muscle wasting, and azoospermia. Plasma fatty acid analysis revealed abnormal values of medium-, long-, and very long-chain fatty acids. Protein expression of SCPx and other enzymes involved in β-oxidation were altered between patient and normal fibroblasts. RNA sequencing and lipidomic analyses identified metabolic pathways that were altered between patient and normal fibroblasts including PPAR signaling, serotonergic signaling, steroid biosynthesis, and fatty acid degradation. Treatment with fenofibrate or 4-hydroxytamoxifen increased SCPx levels, and certain fatty acid levels in patient fibroblasts.

Conclusions: These findings suggest that the patient’s SCP2 mutation resulted in decreased protein levels of SCPx, which may be associated with many metabolic pathways. Increasing SCPx levels through pharmacological interventions may reverse some effects of SCPx deficiency. Collectively, this work provides insight into many of the clinical consequences of SCPx deficiency and provides evidence for potential treatment strategies.

Keywords: Lipid transfer proteins, Lipids/oxidation, Peroxisomes, Cholesterol, Fatty acid
β-oxidation include ABCD1, which aids importation of straight chain VLCFA into peroxisomes, and 2-methylcyl-CoA racemase (AMACR), which converts fatty acids with a methyl group in the (R)-configuration to the (S)-configuration to become substrates for β-oxidation [2].

Human diseases caused by a defect in one of these peroxisomal proteins are called single peroxisomal enzyme deficiencies (PEDs). Patients with PED typically present with severe neurological symptoms. The most common PED is called X-linked adrenoleukodystrophy (X-ALD [MIM: 300371]), which is caused by mutations in the ABCD1 gene, resulting in elevated levels of VLCFA, and most frequently presents with severe cerebral ALD or adrenomyeloneuropathy (AMN) [2]. Other PEDs include ACOX1 deficiency [MIM: 264470], caused by mutations in the ACOX1 gene and reported in about 30 patients; DBP deficiency [MIM: 261515], caused by mutations in the HSD17B4 gene encoding DBP and reported in over 100 patients; and AMACR deficiency [MIM: 614307] caused by mutations in the AMACR gene and reported in about 10 patients [2]. Lastly, PED can be caused by mutations in the SCP2 gene resulting in SCPx deficiency [MIM: 613724], which has previously been reported in only two patients. The first patient reported with SCPx deficiency had a homozygous 1-nucleotide insertion (c.545_546insA) and presented with leukoencephalopathy with motor and peripheral neuropathy, dystonia, hyposmia, nystagmus, and azoospermia [3, 4]. The second patient with SCPx deficiency was a compound heterozygote (c.349C > T and c.121G > T) with spinocerebellar ataxia and brain iron accumulation [4].

The SCP2 gene contains two transcription start sites, resulting in a 58 kDa SCPx and a 15 kDa pro-sterol carrier 2 protein (SCP2) [5]. SCPx is post-translationally cleaved in two, resulting in a 45 kDa thiolase, referred to hereafter as SCPx, including its N-terminus and the remainder with its C-terminus resulting in a 13 kDa mature SCP2 protein. Pro-SCP2 is also processed to form 13 kDa SCP2. Both the 45 kDa SCPx and 13 kDa SCP2 have been implicated in the transport and metabolism of various lipids including sterols [6–8], fatty acids [9–11], phospholipids [8, 12], and fatty acyl-CoAs [13, 14]. SCPx and SCP2 are most highly expressed in tissues involved in the oxidation and trafficking of cholesterol: adrenals, ovary, testis, liver, and intestine [15]. While SCPx is almost exclusively localized to peroxisomes, about 50% of SCP2 is peroxisomal and about 50% is extraperoxisomal (mitochondria, endoplasmic reticulum, and cytosol) [15, 16]. The 45 kDa SCPx exhibits lipid-transfer and sterol-carrier activities and is a 3-ketoacyl-CoA thiolase enzyme that has been shown to be involved in peroxisomal oxidation of branched chain fatty acids, straight chain fatty acids, and the branched side chain of cholesterol [15]. Here, we report a third patient with SCPx deficiency and the first resulting from a missense heterozygous mutation in SCP2. The patient is a 59-year-old male presenting with brainstem neurodegeneration and azoospermia. Whole-genome sequencing revealed a c.572A>G heterozygous mutation resulting in a His191Arg substitution. Patient plasma fatty acid analysis revealed abnormalities in the levels of several fatty acids, including γ- and α-linoleic acid and arachidonic acid. Primary dermal fibroblasts from the patient and control normal human dermal fibroblasts (NHDF) were used to investigate a link between the patient’s SCP2 mutation and its clinical consequences. Western blot analysis revealed a significant reduction in the patient’s SCPx levels compared to NHDF as well as alterations in the levels of many other proteins involved in peroxisomal and mitochondrial β-oxidation. RNA sequencing identified several lipid-related genes that were differentially expressed between patient and normal fibroblasts. Lipidomic analysis identified alterations in several free fatty acids, acylcarnitines, sterols, phospholipids, and sphingolipids involved in metabolic pathways such as steroid and primary bile acid biosynthesis, linoleic metabolism, and fatty acid degradation. Finally, we identified two compounds that have shown to increase SCPx levels and certain fatty acid levels in patient fibroblasts compared to untreated cells. Collectively, our data suggest that the patient’s novel heterozygous SCP2 mutation is associated with alterations in a significant number of genes and lipids that are involved in several critical lipid metabolic pathways, which may contribute to neurodegeneration and testicular defects as seen in the patient.

**Results**

**Identification of a novel heterozygous SCP2 variant**

The patient was a 59-year-old Greek Canadian male with a nine-year history of progressive degenerative neurological disease. This included loss of cranial nerve function with progressive inability to swallow, chew, speak, breathe, or control head movement. Craniospinal imaging studies were negative, and the patient showed no cerebellar problems clinically or radiographically. Taken together, these neurological phenotypes are consistent with brainstem, rather than cerebellar, neurodegeneration. In addition to these neurological defects, the patient also had a history of cardiac dysrhythmia without associated risk factors, and primary hypogonadism with azoospermia and reduced testosterone with elevated follicle-stimulating hormone levels.

Whole-genome sequencing identified a novel c.572A>G heterozygous variant resulting in a p.His191Arg substitution. Table 1 summarizes the results of the patient’s genome-wide scan, including other gene
variants identified. The p.His191Arg substitution was not previously identified in the literature nor in ClinVar or LOVD 3.0 databases. The variant was identified in dbSNP (rs372168791) and in control databases in 11 of 282,548 chromosomes at a frequency of 0.00003893 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in European (non-Finnish) in 9 of 129,022 chromosomes (freq: 0.00007) and “Other” in 2 of 7204 chromosomes (freq: 0.000278) populations, but not observed in African, Latino, Ashkenazi Jewish, East Asian, European (Finnish), or South Asian populations. The p.His191 residue is conserved in mammals and other organisms, and 8 of 8 computational analyses (SIFT, FAHTMM, DANN, MT, MetaLR, Revel, PolyPhen, and MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence, and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, and GeneSplicer) do not predict a difference in splicing. In summary, the clinical significance of this variant could not be determined with certainty and was classified as a variant of uncertain significance from the database search, thus necessitating further work to elucidate the clinical significance of this variant.

Because of the known role of SCPx in fatty acid metabolism, the patient’s plasma fatty acid levels were measured after an overnight fast on two separate occasions. The resulting fatty acid profile (Table 2) shows that many medium-, long-, and very long-chain fatty acids were outside the respective reference range. Reference ranges were derived from the central 95% of data derived from a large group of healthy individuals established by the clinical biochemistry laboratory. Specifically, the patient’s levels of medium-chain fatty acids octanoic acid (8:0) and decenoic acid (10:0) and long-chain fatty acids hexadecadienoic acid (16:2), g-linolenic acid (18:3w6), a-linolenic acid (18:3w3), and arachidic acid (20:0) were below normal. In contrast, the patient’s levels of long-chain fatty acids arachidonic acid (20:4w6) and mead acid (20:3w9) and VLCFA DHA (22:6w3) and nervonic acid (24:1w9) were above normal (Table 2). These abnormalities in the levels of medium-, long-, and very long-chain fatty acids are consistent with the role of SCPx in fatty acid β-oxidation and suggest that both mitochondrial and peroxisomal fatty acid β-oxidation were affected.

Characterization of SCPx and SCP2 in NHDF and WESP cells

Primary fibroblasts (WESP) were generated from the patient, and the heterozygous c.572A > G variant identified by whole-genome sequencing was confirmed by next-generation sequencing (NGS)-based amplicon sequencing. NGS and Basic Local Alignment Search Tool (BLAST) results from WESP cells revealed that about 50% of the reads contained the WT nucleotide, while about 50% of the reads had the c.572A > G mutation, confirming the heterozygous variant in SCP2 identified via whole-genome sequencing (Fig. 1A). Normal human dermal fibroblasts (NHDF) confirmed as WT for SCP2 by sequencing were used as controls to compare levels of SCPx in WESP cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure expression of the SCPx-coding region of the SCP2 gene (shown as SCPX) and showed that there was about 50% lower mRNA expression of this region of SCP2 in WESP.  

| Disease (Inheritance) | Gene (Transcript) | Variant; Zygosity | Variant interpretation | Variant frequency (GnomAD) |
|-----------------------|-------------------|-------------------|-----------------------|---------------------------|
| Osteosclerotic metaphyseal dysplasia (AR); Parkinson’s disease (preliminary evidence, inheritance unknown) | LRRK1 (NM_024652.6) | c.4909A > T; Heterozygous | Variant of uncertain significance | 0 |
| Beta-mannosidosis (AR) | MANBA (NM_005908.3) | c.1622G > A; Heterozygous | Likely pathogenic | 0.000008 |
| Leukoencephalopathy with dystonia and motor neuropathy (AR) | SCP2 (NM_002979.5) | c.572A > G; Heterozygous | Variant of uncertain significance | 0.000004 |
| Dent disease (XLR); Hypophosphatemic rickets (XLR); Nephrolithiasis, type I (XLR); Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis (XLR) | CLCN5 (NM_001127898.4) | c.152G > A; Heterozygous | Variant of uncertain significance | 0.00001265 |
| Hypokalemic periodic paralysis, type 1 (AD); Susceptibility to malignant hyperthermia (AD); Susceptibility to thyrotoxic periodic paralysis (AD) | CACNA1S (NM_000069.3) | c.262A > G; Heterozygous | Variant of uncertain significance | 0.0002369 |

AR Autosomal recessive; AD autosomal dominant; XLR X-linked recessive
cells compared to controls, consistent with a heterozygous mutation (Fig. 1B). There was no difference in the expression of the SCP2-coding region of the SCP2 gene between the two samples since this region has its own promoter (Fig. 1B). Protein levels of SCPx were examined by immunoblot, which showed that there was a significant reduction in the amount of 58 kDa and 45 kDa SCPx in WESP cells compared to NHDF (Fig. 1C). Consistent with qRT-PCR results, there was no difference in levels of 13 kDa SCP2 between the two groups (Fig. 1C). These data validate the whole-genome sequencing results and confirm the presence of a heterozygous variant in the SCPx-coding region of the SCP2 gene, showing that the variant leads to a significant decrease in mRNA expression and protein levels.

**SCPx deficiency is associated with alterations in peroxisome number**

Next, we were interested in identifying potential changes in the abundance of peroxisomes. Alterations in peroxisome abundance have been reported in fibroblasts of patients with other peroxisomal disorders such as Zellweger's disease [MIM: 214100] [17]. To determine any changes in the number of peroxisomes in patient WESP cells, we performed immunocytochemistry using the peroxisomal membrane protein 70 (PMP70), a commonly used peroxisomal marker. We found that patient WESP cells had significantly less peroxisomes than control cells (Fig. 2A–C). As a control, we stained for mitochondria using Mitotracker and found that there was no difference in the number of mitochondria between the two cell types (Fig. 2A–C). We also stained for SCPx, which had significantly decreased levels in patient cells compared to control, consistent with the data in Fig. 1 (Fig. 2A–C). These data show that a decrease in SCPx levels is associated with a decrease in the number of peroxisomes, which is consistent with other peroxisomal disorders associated with neurodegenerative phenotypes.

**Alterations in levels of other peroxisomal and mitochondrial β-oxidation enzymes**

We next wanted to identify any potential changes in other peroxisomal β-oxidation enzymes along the straight-chain fatty acyl-CoA pathway. Figure 3A demonstrates an increase in ACOX1 but a decrease in ACAA1 in patient WESP cells. In contrast, oxidation of 2-methyl-branched fatty acyl-CoAs was not affected as demonstrated by the lack of differences in DBP levels (Fig. 3A). These data suggest that the patient’s SCPx variant may be associated with alterations in the levels of other peroxisomal β-oxidation enzymes, which may affect the metabolism of fatty acids beyond those directly metabolized by SCPx.

As mitochondria are the other main site of fatty acid β-oxidation, we were also interested in measuring the levels of mitochondrial β-oxidation enzymes. Carnitine palmitoyltransferase 1 (CPT1A) is a key enzyme in the transport of long-chain fatty acids across the inner mitochondrial membrane. Immunoblot data showed that CPT1A levels were increased in patient fibroblasts compared to control (Fig. 3B). These data further suggest that the patient’s SCPx variant was accompanied

### Table 2 Patient plasma fatty acid panel

| Fatty acid                  | Patient value (nmol/mL) | Reference value (nmol/mL) |
|-----------------------------|-------------------------|---------------------------|
| 8:0 (Octanoic acid)         | 5                       | 8–47                      |
| 10:1 (Decenoic acid)        | 1.6                     | 1.8–5.0                   |
| 10:0 (Decanoic acid)        | 8                       | 2–18                      |
| 12:1 (Lauroenic acid)       | 2.2                     | 1.4–6.6                   |
| 12:0 (Lauric acid)          | 32                      | 6–90                      |
| 14:2 (Tetradecadienoic acid)| 1.0                     | 0.8–5.0                   |
| 14:1 (Myristoleic acid)     | 5                       | 3–64                      |
| 14:0 (Myristic acid)        | 77                      | 30–150                    |
| 16:2 (Hexadecadienoic acid)| 8                       | 10–48                     |
| 16:1ω9 (Hexadecenoic acid)  | 56                      | 25–105                    |
| 16:1ω7 (Palmitoleic acid)   | 171                     | 110–1130                  |
| 16:0 (Palmitic acid)        | 2307                    | 1480–3730                 |
| 18:3ω9 (g-Linoleic acid)    | 14                      | 16–150                    |
| 18:3ω3 (α-Linoleic acid)    | 40                      | 50–130                    |
| 18:2ω6 (Linoleic acid)      | 2854                    | 2270–3850                 |
| 18:1ω9 (Oleic acid)         | 1893                    | 650–3500                  |
| 18:1ω7 (Vaccenic acid)      | 341                     | 280–740                   |
| 18:0 (Stearic acid)         | 712                     | 590–1170                  |
| 20:5ω3 (EPA)                | 29                      | 14–100                    |
| 20:4ω6 (Arachidonic acid)   | 1555                    | 520–1490                  |
| 20:3ω9 (Mead acid)          | 87                      | 7–30                      |
| 20:3ω6 (h-g-Linolenic acid) | 166                     | 50–250                    |
| 20:0 (Arachidic acid)       | 42                      | 50–90                     |
| 22:6ω3 (DHA)                | 318                     | 30–250                    |
| 22:5ω6 (DPA)                | 43                      | 10–70                     |
| 22:5ω3 (DPA)                | 125                     | 20–210                    |
| 22:4ω6 (DTA)                | 77                      | 10–80                     |
| 22:1 (Docosenoic acid)      | 10                      | 4–13                      |
| 22:0 (Docosanoic acid)      | 508                     | 0.0–963                   |
| 24:1ω9 (Nervonic acid)      | 119                     | 60–100                    |
| 24:0 (Tetracosanoic acid)   | 408                     | 0.0–91.4                  |
| 26:1 (Hexacosanoic acid)    | 0.7                     | 0.3–0.7                   |
| 26:0 (Hexacosanoic acid)    | 0.48                    | 0.00–1.30                 |
| 15:0(CH3)4 (Pristanic acid)| 0.09                    | 0.00–2.98                 |
| 16:0(CH3)4 (Phytanic acid)  | 0.88                    | 0.00–9.88                 |
| Total Fatty Acids           | 11.2 mmol/L             | 7.3–16.8 mmol/L           |

Fatty acids in bold indicate fatty acids out of the reference range.
by alterations in mitochondrial fatty acid β-oxidation in addition to its effects on peroxisomal β-oxidation.

To assess other putative pathways influenced by SCPx, we next examined levels of peroxisome proliferator-activated receptor α (PPARα), a nuclear receptor that regulates the expression of genes involved in fatty acid β-oxidation [18]. Immunoblotting data showed that PPARα was increased in patient fibroblasts compared to control cells, consistent with the increased expression of PPARα-responsive genes in Sbp2 gene-ablated mice (Fig. 3C) [19]. Additionally, given

![Fig. 1](image_url) Characterization of SCP2 mutation in patient fibroblasts. A BLAST DNA sequence of amplicon-based NGS results of SCP2 in patient fibroblasts (WESP) compared to the human wild-type (WT) sequence. Green box shows A > G mutation present in half the reads (top) and WT nucleotide in half the reads (bottom). B qRT-PCR analyses of the SCPx coding region of SCP2 (left) and the SCP2 coding region of SCP2 (right), where data are normalized to GAPDH. Data are shown as mean ± SEM (n = 3). ***p < 0.001. C Western blot analyses of SCPx and SCP2 in control fibroblasts (NHDF) and WESP cells.
Fig. 2 Quantification of peroxisome abundance in NHDF and WESP cells. **A** Confocal microscopy image of NHDF stained with Mitotracker, PMP70 (peroxisomes), SCPx, and DAPI. Scale bar: 20 µm. **B** Confocal microscopy images of a WESP fibroblast stained with Mitotracker, PMP70 (peroxisomes), SCPx, and DAPI. Scale bar: 20 µm. **C** Quantification of confocal images. The area of staining with each marker was quantified in 10 images per sample using ImageJ. Data are shown as mean ± SEM (n = 10). **p < 0.01; ***p < 0.001
the recognized role of SCPx in bile acid synthesis, we next measured levels of cholesterol 7α-hydroxylase (CYP7A1), a rate-limiting step in this process [20]. We found that levels of CYP7A1 were increased in patient fibroblasts compared to control cells, which is in line with a previous report citing CYP7A1 repression in SCP2-overexpressing human hepatocytes (Fig. 3C) [21].

RNA-sequencing identified differentially expressed genes and altered pathways related to lipid trafficking and metabolism

The observed effects on fatty acid β-oxidation and on bile acid synthesis prompted us to seek a broader view of alterations in the patient’s transcriptome. To this end, we sought to identify differential expression of genes governing lipid transport and metabolism. RNA sequencing data were confirmed by RT-qPCR of several lipid-related genes (Fig. 4). We uploaded our DEG list generated through Partek Genomic Flow into
Fig. 4 Confirmation of differentially expressed genes identified by RNA sequencing. A qRT-PCR analyses of differentially expressed genes part of the “cholesterol” interaction network. B qRT-PCR analyses of differentially expressed genes part of the “lipid” interaction network. C qRT-PCR analyses of differentially expressed genes part of other interaction networks. Data are shown as mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001
Ingenuity Pathway Analysis (IPA). Overlaying the DEG list with the “cholesterol” interaction network identified significantly decreased expression of: FABP4 [MIM: 600434], ANGPTL4 [MIM: 605910], ABCA1 [MIM: 600406], KCNJ [MIM: 601534], LIPG [MIM: 603684], NPC2 [MIM: 601015], G6PAT [MIM: 610958], OSBP2 [MIM: 606729], PLA2G4A [MIM: 600522], PLIN2 [MIM: 103195], and PSEN2 [MIM: 600759]. In contrast, CYP1B1 [MIM: 601771] and INHBA [MIM: 147290] were significantly increased in WESP cells compared to NHDF (Fig. 4A). We pursued a similar strategy in addressing the “lipid” interaction network. This strategy yielded significantly reduced expression of AR [MIM: 313700], ESR1 [MIM: 133430], NR0B1 [MIM: 300473], and SYT1 [MIM: 185605] in WESP cells compared to NHDF (Fig. 4B). This process was also done with other interaction networks including that of phospholipids, SCP2, testosterone, and steroidogenic acute regulatory protein (STAR), which is known to play a critical role in cholesterol transport for steroidogenesis [22]. These yielded the identification of many genes that were also found in our cholesterol and lipid interaction searches, but also the addition of PPAR [MIM: 601487] for the phospholipid interaction network, CACNA1A [MIM: 601011] for the SCP2 interaction network, MAOA [MIM: 309850] for the testosterone interaction network, and PTGER2 [MIM: 176804] for the STAR interaction network, each of which were decreased in WESP cells compared to NHDF (Fig. 4C).

To identify pathways that may be altered due to changes in the patient’s transcriptome, we uploaded the DEG list that was confirmed by RT-qPCR into MetaboAnalyst 5.0. This online platform mapped the DEG list onto affected pathways (Table 3). The top affected pathway identified by MetaboAnalyst 5.0 was cholesterol metabolism, which aligns with known functions of SCPx in metabolism of cholesterol for bile acid synthesis and in cholesterol transport. The genes that are part of the cholesterol metabolism pathway that were confirmed to be differentially expressed between NHDF and WESP cells were ABCA1, LIPG, ANGPTL4, and NPC2. Another pathway that may be affected due to alterations in the expression of several genes is PPAR signaling, which is an important regulator of many genes critical for peroxisomal β-oxidation. DEG in this pathway included FABP4, ANGPTL4, PLIN2, and PPAR. Additionally, another pathway with many genes shown to be differentially expressed was that of serotonergic synapse signaling. DEG in this pathway included CACNA1A, PLA2G4A, and MAOA.

### Table 3 Summary of RNA-sequencing-derived pathways

| Pathway                        | Gene        |
|--------------------------------|-------------|
| Cholesterol metabolism         | ABCA1       |
|                                | LIPG        |
|                                | ANGPTL4     |
|                                | NPC2        |
| PPAR signaling                 | FABP4       |
|                                | ANGPTL4     |
|                                | PLIN2       |
|                                | PPARG       |
| Serotonergic synapse            | CACNA1A     |
|                                | PLA2G4A     |
|                                | MAOA        |

**Alterations in free fatty acid levels and related pathways**

The identification of many altered fatty acids in the patient’s plasma fatty acid profile and of many lipid-related pathways from our RNA sequencing analysis prompted us to investigate other potential changes in the patient’s lipidome. We conducted lipidomic analysis using NHDF and WESP cells for different classes of lipids including free fatty acids, acylcarnitines, sterols, phospholipids, and sphingolipids. Significant differences in the levels of many free fatty acid species identified through lipidomic analysis were consistent with the abnormalities in several fatty acid species derived from the patient’s plasma. For example, arachidonic acid (20:4), mead acid (20:3w9), and DHA (22:6) were out of normal range or altered in both the patient’s plasma and his fibroblasts (Table 1 and Fig. 5A). However, there were also several fatty acids that were significantly altered in WESP cells that were not detected in the patient’s plasma fatty acid profile. These included lauric acid (12:0), eicosatrienoic acid (20:3), EPA (20:5), DPA (22:5), and DTA (22:4) (Table 1 and Fig. 4A). Additionally, we noted that nervonic acid (24:1) was higher than normal in the patient’s plasma, but significantly lower than that seen in NHDF in our fibroblast lipidomic analysis. The discrepancies between the patient’s plasma fatty acid profile and the cellular lipidomic data may be attributed to differing extra- and intra-cellular levels of these lipids. Nevertheless, the significant differences in many species of free fatty acid levels between NHDF and WESP cells may further point to the pivotal role of SCPx in fatty acid metabolism.

To further identify potential pathways that could be affected as a result of perturbed free fatty acids, we used MetaboAnalyst 5.0 to map the lipidomic data onto pathways (Table 4). One of the pathways that involves several free fatty acids that were significantly altered between NHDF and WESP cells is the biosynthesis of unsaturated fatty acids. This pathway included EPA (20:5), DPA (22:5), DHA (22:6), eicosatrienoic acid (20:3 N9), arachidonic...
acid (20:4), adrenic acid (22:4), and icosenoic acid (20:1). Additionally, the linoleic acid metabolism pathway was altered with changes in the levels of arachidonic acid (20:4) and eicosatrienoic acid (20:3 N9). In addition to these lipids, *PLA2G4A*, which was part of our DEG list, is also part of this pathway. These data further suggest that
the metabolism of several fatty acids is associated with reduced SCPx.

Alterations in acylcarnitine levels and related pathways
Since SCPx is known to play a critical role in fatty acid β oxidation and because we noted differences in levels of mitochondrial fatty acid β oxidation enzymes between NHDF and WESP cells, we next turned our attention to acylcarnitine. We found that the levels of several acylcarnitine species were significantly increased in WESP cells compared to NHDF (Fig. 5B). Consistent with this observation, MetaboAnalyst 5.0 identified CAR 16:0 as part of the fatty acid degradation pathway (Table 4). These data suggest that the SCP2 variant may also be associated with alterations in mitochondrial fatty acid β oxidation, since acylcarnitines are required for fatty acid transport into mitochondria for β oxidation.

Alterations in sterol levels and related pathways
As a known sterol transfer protein and important enzyme in cholesterol metabolism, we were also interested in identifying potential changes in sterol levels between NHDF and WESP cells. Lipidomic analysis identified that the levels of 14-demethyl-lanosterol, 24-hydroxycholesterol, 7α-hydroxycholesterol, 7-ketocholesterol, 8-dehydrocholesterol, 24,25-dehydrolanosterol, 7α-hydroxy-4-cholesten-3-one, 4,4-dimethyl-choleste-8(9)-en3β-ol, zymostenol, and zymosterol were all significantly lower, while 25-hydroxycholesterol was significantly higher in WESP cells compared to NHDF (Fig. 5C). These alterations in sterol levels are consistent with the known role of SCPx in sterol transport and metabolism.

We also identified pathways that may be altered due to the changes in sterol levels in patient fibroblasts (Table 4). Interestingly, one of the affected pathways was steroid biosynthesis, which included 24,25-dehidrolanosterol, lanosterol, 14-demethyl-lanosterol, zymostenol, and zymosterol. The alteration in the levels of these sterols that are part of the steroid biosynthetic pathway may be associated with the hypogonadism seen in this patient. Another pathway that was significantly altered by the changes in sterol levels is primary bile acid biosynthesis. This pathway involves 25-hydroxycholesterol, 7α-hydroxycholesterol, and 7α-hydroxy-4-cholesten-3-one. These data are consistent with the role of SCPx in cholesterol metabolism for bile acid synthesis.

| Lipid class | Pathway | Lipid | Gene | Direction | p value/fold change |
|-------------|---------|-------|------|-----------|-------------------|
| Sterol      | Steroid biosynthesis | 24,25-Dihydrolanosterol | Decreased | 0.0056 |
|             |         | Lanosterol | Decreased | <0.0001 |
|             |         | 14-Demethyl-lanosterol | Decreased | 0.0004 |
|             |         | Zymosterol | Decreased | 0.0001 |
|             |         | Zymostenol | Decreased | 0.0106 |
| Primary bile acid biosynthesis | 25-Hydroxycholesterol | Increased | <0.0001 |
|             |         | 7alpha-Hydroxycholesterol | Decreased | 0.0025 |
|             |         | 7alpha-hydroxy-4-cholesten-3-one | Decreased | 0.0013 |
| Free fatty acid | Biosynthesis of unsaturated fatty acids | 20:5 (Eicosapentaenoic acid) | Increased | <0.0001 |
|             |         | 22:5 (Docosapentaenoic acid) | Increased | <0.0001 |
|             |         | 22:6 (Docosahexaenoic acid) | Increased | <0.0001 |
|             |         | 20:3 N9 (Eicosatrienoic acid) | Decreased | 0.0037 |
|             |         | 20:4 (Arachidonic acid) | Increased | <0.0001 |
|             |         | 22:4 (Arachidonic acid) | Increased | <0.0001 |
|             |         | 20:1 (Icosenoic acid) | Decreased | 0.0199 |
| Linoleic acid metabolism | 20:4 (Arachidonic acid) | Increased | <0.0001 |
|             |         | 20:3 N9 (Eicosatrienoic acid) | Decreased | 0.0037 |
| Phospholipid | Glycerophospholipid metabolism | Phosphatidyglycerol | Increased | 0.0189 |
|             |         | Phosphatidylserine | Increased | 0.0072 |
|             |         | PLA2G4A | Decreased | –8.14 |
|             |         | PLA2G4A | Decreased | –8.14 |
| Acylcarnitine | Fatty acid degradation | CAR 16:0 | Decreased | 10.64 |
|             |         | (L-palmitoylcarnitine) | Increased | 0.0004 |

*p values are shown for lipids and fold changes are shown for genes.*
Alterations in phospholipid levels and related pathways
As indicated earlier, SCPx may play a role in the transport and/or metabolism of phospholipids [8, 12]. Our lipidomic analysis found that the amount of phosphatidylglycerol (PG) and phosphatidylserine (PS) were significantly higher in WESP cells compared to NHDF (Fig. 5D). These phospholipids are part of the glycerophospholipid metabolism pathway, in addition to PLA2G4A and GPAT4 from our DEG list (Table 4). These data are aligned with the putative role of SCPx in phospholipid metabolism.

Alterations in sphingolipid levels
We were also interested in identifying alterations in levels of sphingolipids since certain sphingolipids are highly enriched in the central nervous system and play critical roles in neuronal growth and differentiation. Additionally, abnormal levels of sphingolipids such as ceramides are often found in patients with neurodegeneration [23]. We found that many ceramide species had varying levels between control NHDF fibroblasts and patient WESP fibroblasts including CER d18:0/24:1, CER d18:1/22:5, CER d18:1/24:0, CER d18:1/24:1, CER d18:1/26:0, and CER d18:2/26:1 (Fig. 5E). Each of these ceramide species had significantly lower levels in patient fibroblasts compared to control. Because ceramide levels are determined in part by the ceramide/sphingomyelin cycle in which ceramide can be both produced from sphingomyelin or metabolized to sphingomyelin, we also measured sphingomyelin levels in both cell types [24]. Interestingly, while there were many species of ceramides that were decreased in WESP cells compared to NHDF, there were only two sphingomyelin species that had significantly different levels SM 32:2 and SM 44:2 (Fig. 5E). This suggests that, although the ceramide/sphingomyelin cycle may be functioning normally, there may be alterations in other pathways of ceramide production, such as from de novo synthesis or from the ceramide salvage pathway [24]. The varying levels in sphingolipids between control and patient cells also suggest that altered ceramide levels may play a role in the patient’s neurodegenerative phenotype. Collectively, our lipidomic data show that SCPx deficiency is accompanied by reorganization of the patient’s lipidome, which may provide insight into some of the patient’s clinical presentations.

Identification of compounds that increase SCPx expression
Because the patient’s SCP2 mutation results in decreased SCPx expression and is associated with alterations in lipid metabolism, we screened for compounds that could restore SCPx levels. Prompted by our differential expression profiling pointing to possible PPAR involvement, we treated patient and control fibroblasts with fenofibrate, a widely adopted PPARα agonist for treatment of dyslipidemia [25]. Unlike in normal fibroblasts which were relatively unaffected, patient WESP cells showed an increase in SCPx levels following fenofibrate treatment (Fig. 6A). As a previous report also showed that the selective estrogen receptor modulator 4-hydroxytamoxifen (4-OHT), also known as afimoxifene, can increase SCPx expression in DL23 cells [26], we also tested this compound. We found that 4-OHT treatment significantly and selectively increased SCPx levels compared to untreated patient cells (Fig. 6B). These data suggest that 4-OHT may also be a viable strategy for increasing SCPx levels in conditions characterized by SCPx deficiency.

Since fenofibrate and 4-OHT have separate mechanisms of action, we hypothesized that a combination treatment of the two may have synergistic effects in increasing SCPx expression. However, treating patient fibroblasts with fenofibrate and 4-OHT resulted in no additional increases from those observed with either compound alone (Fig. 6C). This shows that, while these drugs can independently increase SCPx levels, they do not work synergistically on this target.

Fenofibrate and 4-OHT improve the patient’s fatty acid profile
Finally, we wanted to investigate whether increasing SCPx expression through fenofibrate or 4-OHT is sufficient to restore the patient’s free fatty acid levels. We analyzed free fatty acid levels in NHDF and WESP cells treated with fenofibrate alone, 4-OHT alone, or fenofibrate and 4-OHT in combination for 24 h. The complete fatty acid profiles including the levels of all species identified following treatments are detailed in Additional file 3. We confirmed that many fatty acid species in the patient’s cells were increased following treatment with fenofibrate, including 16:0, 17:0, 18:0, 18:2, 18:3 N3, 18:3 N6, 18:4, 20:5, and 22:4 (Fig. 7). Further, total free fatty acids in patient cells were also significantly increased by fenofibrate treatment. Similarly, 4-OHT treatment demonstrated a positive effect on fatty acid levels including: 16:0, 18:2, 18:3 N6, and 22:6 (Fig. 7). However, in general, 4-OHT was not as effective in increasing fatty acid levels as fenofibrate. Additionally, the combination of drugs did not exhibit a synergistic effect on fatty acid levels. Collectively, these data show that treatment with fenofibrate or 4-OHT alone can improve the fatty acid profile in patient cells and provide evidence that these compounds may be beneficial in the treatment of SCPx deficiency.

Discussion
Here, we report a patient presenting with progressive neurodegeneration including loss of cranial nerve function affecting the patient’s ability to swallow, chew, speak, breathe, and control head movement. Additionally, the
patient has history of primary hypogonadism with azoospermia. Upon whole-genome sequencing, genetic variants were identified in the following genes: \textit{LRRK1}, \textit{MANBA}, \textit{CLCN5}, \textit{CACNA1S}, and \textit{SCP2}. \textit{LRRK1} encodes a leucine-rich repeat kinase shown to function in the regulation of bone resorption [27]. Mutations in \textit{LRRK1} have been shown to cause osteosclerotic metaphyseal dysplasia [MIM: 615198], a rare skeletal dysplasia characterized by osteosclerosis of the long bones [27, 28]. In addition, one report using whole exome sequencing in two Parkinson’s disease (PD) patients identified variants in \textit{LRRK1} (among other genes) [29]. However, a causative relationship was not shown since protein expression was unaffected. Next, mutations in \textit{MANBA}, which encodes β-mannosidase, have been found to cause β-mannosidosis [MIM: 248510], a lysosomal storage disorder most commonly characterized by mental retardation, hearing loss, and frequent infections [30, 31]. The \textit{CLCN5} gene encodes a voltage-gated chloride ion channel, and mutations in this gene have been associated with several diseases all characterized by progressive proximal renal tubulopathy including Dent disease [MIM: 300009], X-linked recessive nephrolithiasis [MIM: 310468], X-linked recessive hypophosphatemia rickets [32].

\textbf{Fig. 6} SCPx protein levels in WESP cells in response to fenofibrate and 4-hydroxytamoxifen treatment. A Western blot analyses of samples treated with various concentrations of fenofibrate for 24 h (left) and quantification of the blots (right). B Western blot analyses of samples treated with various concentrations of 4-hydroxytamoxifen (4-OHT) for 24 h (left) and quantification of the blots (right). C Western blot analyses of samples treated with 25 µM fenofibrate, 0.5 µM 4-OHT, and the fenofibrate + 4-OHT combination for 24 h (left) and the quantification of the blots (right). All Western blots were conducted in triplicate. Quantification was done using ImageJ analyses after normalizing to the untreated band for each group followed by normalizing to GAPDH. Data are shown as mean ± SEM (n = 3). *p < 0.05; **p < 0.01.
Fig. 7  Fatty acid profile of NHDF and WESP cells following treatment. Measurement of various species of free fatty acids after treatment with 25 µM fenofibrate, 0.5 µM 4-hydroxytamoxifen, or a combination of the two compounds for 24 h. Data are shown as mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001
not the absence, of SCPx. Additionally, although previous work in SCPx-null mice has increases in β-oxidation enzymes in the absence of SCPx [1, 38]. The increase in PPARα levels in WESP cells shown here may be responsible for the observed increases in ACOX1 and CPT1A. The latter being recognized targets of PPARα action [46–50]. However, we also noted a decrease in ACAAA1, which is consistent with its negative regulation by PPARα [51]. Because ACAAA1 is responsible for catalyzing the same step of the β-oxidation pathway as SCPx (but with different substrates), the decrease in ACAAA1 levels may further explain the severity in the phenotype associated with SCPx deficiency, since both peroxisomal β-oxidation pathways are affected [39]. In addition to PPARα and the β-oxidation enzymes, we also found that levels of CYP7A1 are increased in WESP cells compared to NHDF, which is consistent with what was seen in SCP2-deficient mice [52]. Although fibroblasts do not synthesize bile acids, these data provide insight into what may be found when studying more relevant tissues.

Our RNA sequencing and lipidomic data identified several metabolic pathways that have genes and/or lipids that are altered between NHDF and WESP fibroblasts. Some of these pathways include steroid biosynthesis and serotonergic signaling, which are relevant to the patient’s testicular and neurological phenotypes, respectively. Cholesterol is the precursor of all steroid hormones, including testosterone, and thus, alterations in the metabolism of cholesterol may affect steroid biosynthesis and lead to low testosterone levels, accounting for the patient’s hypogonadism [53]. The patient’s low testosterone levels may also explain his azoospermia, since testosterone is also necessary for spermatogenesis and male fertility [54, 55]. Another pathway that was identified and may provide insight into the patient’s phenotype
was serotonergic signaling, which included many downregulated genes. Alterations in serotonin signaling may contribute to various neurodevelopmental disorders [56]. Additionally, previous studies have suggested that inducing serotonergic signaling may be beneficial in slowing the progression of other neurodegenerative diseases such as Alzheimer’s disease [MIM: 104300] [57, 58]. Thus, altered serotonergic signaling may explain certain aspects of the patient’s neurodegenerative phenotype. Taken together, our gene expression, lipidomic, and pathway analyses provide further insight into the biochemical basis of the patient’s striking clinical presentation.

There are several reasons for which the SCP2 variant may have resulted in a widespread alteration of genes and lipids contributing to the clinical presentations seen in the patient. Here, we showed that the SCP2 variant resulted in a reduction of the levels of some lipids and an accumulation of other lipids, which may result in a decreased supply or toxic levels of those lipids, respectively. Firstly, defects in β-oxidation may reduce the supply of energy needed by certain tissues. For example, fatty acids are used for the production of ketone bodies, which are a vital source of fuel for the brain to spare glucose for other uses [59]. With reduced supply of ketone bodies, glucose utilization may increase, further decreasing the availability of glucose to support major processes [59]. Although poorly understood, it has been suggested that reprogramming of certain tissues to rely on glucose for energy when fatty acids are unavailable is mediated by widespread alterations in gene expression [60]. Additionally, decreased hepatic ATP production may lead to hyperammonemia which causes defects in the urea cycle, resulting in encephalopathy [59]. Further, decreased energy supply to skeletal muscle and cardiac muscle, which rely heavily on the β-oxidation of long-chain fatty acids for energy, results in muscle weakness or hypotonia and hypertrophy of the myocardium, respectively [59]. Another explanation for the patient’s presentations given the data shown here is toxicity due to an accumulation of metabolites. Many intermediates of β-oxidation have been reported to be toxic including C8-C10 and 3-hydroxy C12-C16 [59]. An accumulation of these metabolites has been shown to have several toxic effects such as increased ROS generation, uncoupled oxidative phosphorylation, and interference with DHA metabolism which may result in clinical consequences including encephalopathy, muscle weakness, cardiac arrhythmias, polyneuropathy, and demyelination [61–66].

To begin to translate our findings to the bedside, we sought to identify compounds that could restore SCPx levels. Previous reports have shown that SCP2 is a PPARα responsive gene and that some PPARα ligands can increase SCP2 expression [67–69]. Additionally, based on our findings that the patient’s SCP2 mutation is associated with a decrease in peroxisome abundance and to alterations in PPAR signaling, we hypothesized that treatment of patient fibroblasts with a PPARα agonist may be a viable intervention. Indeed, treatment with fenofibrate increased SCPx levels in patient WESP fibroblasts. Moreover, we identified that 4-OHT, a selective estrogen receptor modulator, also increased SCPx expression. While unclear, our patient’s cell responsiveness may be afforded by their endogenously downregulated ESR1 gene expression. We also found that while fenofibrate or 4-OHT treatment induced SCPx levels in patient fibroblasts, normal fibroblasts were relatively unaffected. This may be due to a negative feedback mechanism on PPARα activity under normal conditions to control fatty acid oxidation as in control fibroblasts, but increased PPARα activity in response to fenofibrate when fatty acid oxidation is disrupted as in patient fibroblasts. Lastly, we identified that treatment with fenofibrate or 4-OHT improves the fatty acid profile of patient fibroblasts. It should be noted, however, that the sample size used for the data in Fig. 7 was smaller than that used in Fig. 5, which may explain differences in the control NHDF and WESP free fatty acid levels between the two data sets. Nevertheless, our data indicate a reorganization of the lipid profile of patient fibroblasts compared to control and point to the potential use of fenofibrate or 4-OHT as treatments for SCPx deficiency.

Conclusions
In conclusion, our work describes the first patient with a heterozygous SCP2 mutation resulting in reduced protein expression. The patient presented with azoospermia, cardiac dysrhythmia, muscle wasting, and brainstem neurodegeneration. This work suggests that a reduction in SCPx levels may contribute to widespread gene alterations and dysregulated lipid synthesis and metabolism. Our identification that fenofibrate and 4-OHT can restore SCPx protein levels and related functions should prompt future studies into their role for neurodegenerative peroxisomal disorders.

Methods
Genome sequencing
Whole-genome sequencing was performed on whole blood using next-generation sequencing (NGS) on the Illumina NovaSeq 6000 platform. 98% percent of the exome was sequenced at greater or equal to 10X depth coverage. Library preparation was performed using the Illumina TruSeq PCR-free library preparation kit according to the manufacturer’s instructions. Seven hundred micrograms of DNA was fragmented to 400 bp by acoustic shearing using a Covaris LE220 instrument (Covaris
Inc., Woburn, MA). Library size range was assessed using a Bioanalyzer (Agilent Technologies, Santa Clara, USA) and quantified with a Kapa library quantification kit (Roche Sequencing and Life Sciences, Wilmington, MA, USA). Genomic libraries were loaded on an Illumina patterned flowcell and followed by cluster generation and 150-bases paired-end sequencing on Illumina HiSeq X platform to generate 90–100 g bases of raw data per library. Sequencing of the DNA was performed on a research basis at the Center for Applied Genomics (TCAG; Hospital for Sick Children, Toronto, ON, Canada).

Data processing and analysis was performed using 1) the Franklin Genoox Platform (genoox.com) and 2) local GATK best practices (GATK 3.7). Reads were aligned using Burrows-Wheeler Aligner (BWA) against the hg19 reference genome. Duplicate reads were removed. Variant calling was performed using GATK (version 4.1) and FreeBayes (version 1.1.0). 2. Base calling was performed using bcl2fastq 2.20 (for HiSeq 2500) or HiSeq Analysis software (for HiSeq X). Reads were mapped to the b37 reference genome using the BWA-mem algorithm, and duplicate reads were marked using Picard Tools. Local realignment and base quality score recalibration using GATK followed. Variants were called using GATK HaplotypeCaller. For whole-genome sequencing (WGS), variant quality score recalibration (VQSR) was performed for filtering variants. Variants were identified for further analysis. Human phenotype ontology (HPO) was used to query for genes related to the phenotypic presentation including terms for neurological, neuromuscular, and musculoskeletal search terms.

Clinical samples
This individual was enrolled in the Adults with Undiagnosed Rare Disease genome sequencing research study approved by the Mount Sinai Hospital Research Ethics Board (#12–0222-E) [70]. These studies abide by the Declaration of Helsinki principles.

Cell culture
Patient fibroblasts (WESP) were maintained in minimum essential medium α (MEM α) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO, USA). Adult normal human dermal fibroblasts (NHDF) were acquired from PromoCell and grown in Fibroblast Growth Medium 2 with SupplementMix (PromoCell GmbH, Heidelberg, Germany). Fibroblasts were grown at 37 °C and 5% CO₂.

Cells were treated with 1, 10, or 25 µM fenofibrate (Sigma, St. Louis, MO, USA) or 0.1, 0.5, or 1 µM (Z)-4-hydroxytamoxifen (Sigma-Aldrich, St. Louis, MO, USA) for 24 h prior to cell pellet collection for downstream analyses. For combination treatments, 25 µM fenofibrate and 0.5 µM (Z)-4-hydroxytamoxifen were used to treat the cells for 24 h prior to cell pellet collection.

Next-generation sequencing
Amplicon-EZ sequencing was done in triplicate to confirm the c.572A > G mutation in WESP cells and to confirm that NHDF cells had wild-type (WT) SCP2 (GENEWIZ from Azenta Life Sciences, South Plainfield, NJ, USA). Basic Local Alignment Search Tool (BLAST) was used to align the WT human SCP2 gene with next-generation sequencing results from WESP samples (National Center for Biotechnology Information, Bethesda, MD, USA).

Quantitative real-time polymerase chain reaction
The Quick-RNA MiniPrep Plus kit (Zymo Research, Irvine, CA, USA) was used to extract total RNA for all qRT-PCR data shown. In total, 500 ng of extracted RNA per sample was used for reverse transcription using PrimeScript RT Master Mix (Takara Bio, Mountain View, CA, USA). qRT-PCR was done using Applied Biosystems PowerUP SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) and qTOWER3 (Analytik Jena AG, Jena Germany). Primer information is detailed in Additional file 2. Relative expression levels of genes were calculated by subtracting the cycle threshold value (Ct) from the detection limit (40 Ct) resulting in the ΔCt value, then by taking the log2 of the -ΔCt. Gene expression data were normalized to GAPDH.

Immunoblot analysis
Immunoblot analysis was carried out as previously described [71]. Briefly, total protein was extracted from fibroblasts using RIPA buffer with Pierce Protease Inhibitor and protein concentration was measured using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific). 7.5 µg of protein per sample, and a 4–20% Tris–glycine gradient gel were used for SDS-PAGE (Bio-Rad, Hercules, CA, USA). Protein was transferred to a polyvinylidene fluoride membrane. 5% bovine serum albumin in PBST was used for all blocking steps (Equitech-Bio, Kerrville, TX, USA). All primary antibodies were incubated in blocking solution overnight at 4 °C. Information about antibodies is detailed in Additional file 1. Secondary antibodies were incubated for 1 h at room temperature. Restore Western Blot Stripping Buffer was used to strip the membranes (Thermo Fisher Scientific). Membranes were visualized by Radiance Peroxide and Radiance Plus (Azure Biosystems, Dublin, CA, USA). Immunoreactive proteins were imaged using the Azure c600 (Azure Biosystems).
Immunofluorescence
Fibroblasts were plated at a density of 200,000 cells per well on coverslips for 24 h. Cells were stained with 0.1 μM Mitotracker Red CMXRos for 30 min at 37 °C, washed with PBS 3 times, and fixed with 4% PFA for 10 min at room temperature (Thermo Fisher Scientific). Cells were washed, incubated in 0.1% Triton X-100 for 10 min at room temperature, and washed again. Samples were blocked with 5% donkey serum, washed, and incubated with primary antibodies overnight at 4 °C. After washing, secondary antibodies were added for 30 min at room temperature and then washed again. Cells were stained with DAPI and observed using a Zeiss LSM 880 confocal microscope. Quantification was done using ImageJ.

RNA sequencing
Three replicates per sample were sent for total cell RNA sequencing. RNA extraction and preparation was done according to protocol using the Qiagen Allprep RNA/DNA isolation kit (Qiagen, Valencia, CA, USA). For library preparation, the Clontech Takara SMARTer Total RNA Stranded Pico V2 Library prep kit was used (Takara Bio). Libraries were dual index 8 bp and Illumina Adapters were used. The libraries were sequenced on a Nextseq500 at 2 × 75 cycles. Partek Genomics Suite was used to analyze the gene expression data and to identify differentially expressed genes between WESP and NHDF samples. Significantly differentially expressed genes were identified using FDR < 0.05 and fold change < −2 or > 2 as cutoffs.

Lipidomic analyses
Five replicates of WESP cells and five replicates of NHDF cells with 4 million cells per sample were used for lipidomic analysis, which was performed at the UCSD Lipidomics Core. Lipidomic analytical procedures were conducted as described previously [72]. Briefly, for free fatty acid analysis, 500 μl MeOH was added to 50 μl of sample for extraction. This was followed by the subsequent addition of 25 μl 1 N HCl and 100 μl of 0.1 ng Internal Standard Mix of 12:0-d23,14:0-d27,15:0-d29,16:0-d31,18:0-d35,18:1-d17,18:2-d11,20:4-d11,20:5-d5, 22:6-d5, and 24:0-d47 (Cayman Chemical Company, Ann Arbor, MI, USA). The samples were vortexed and centrifuged, and the iso-octane layer was collected. Solvent was removed. The samples were reconstituted in 50 μl NP Buffer A (59/40/1 IPA/HEX, H₂O containing 10 mM NH₄OAC). For LC–MS analysis, the samples were reconstituted in 50 μl 90% MeOH and 0.1% formic acid. 10 μl per sample was injected into a Waters Acquity UPLC System interfaced with an AB Sciex 6500 QTrap mass spectrometer (Sciex, Framingham, MA, USA). A Phenomenex Kinetics C18 2.1 × 150 mm 1.7μm column was used for chromatographic separation using a step gradient from 100% buffer A (100% 10 mM ammonium acetate in water to 100% buffer B (70/30 isopropanol/acetonitrile/10 mM ammonium acetate) for 10 min. Acylcarnitines were separated by mass spectrometry using MRM scans in positive mode consisting of precursors for Q1 and m/z 85 for Q3. Data analysis was done using Analyst and Multiquant software [74].

Sterols were extracted by adding 500 μl butanol/methanol (3:1) and 250 μl 1 N NaOH to 100 μl of sample. An internal standard mix of 25-Hydroxycholesterol-d₆, Desmosterol-d₆, and Campesterol-d₆ was added to 50μL of homogenate (Avanti Polar Lipids, Birmingham, AL, USA). Samples were saponified for 1.5 h at 37°C with a final concentration of 0.2 N KOH. Samples were extracted by modified BUME. Extracts were brought to dryness and taken up in 90% methanol in water and run on a Waters Acquity UPLC System interfaced with an AB Sciex 6500 QTrap mass spectrometer equipped with an APCI source. Probe settings were: Curtain Gas=20, Collision Gas=Medium, Ion Spray Voltage=5500, Temperature=400, GS1=25, NC=1. A Phenomenex Kinetex C18 1.7μm 2.1 mm x 150 mm column was used for chromatographic separation. A 30-min step gradient was employed using 70/30 acetonitrile/water with 5 mM ammonium acetate as Buffer A and 50/50 acetonitrile/water with 5 mM ammonium acetate as Buffer B with a flow of 0.5 mL/min. The gradient started at 0%B for 2 min, ramped to 10%B over 4 min, 15%B over 9 min, 50%B over 11 min, 100%B over 2 min, then held at 100%B for 2 min. Sterol species were identified by mass spectrometry using 30 MRMs (multiple reaction monitoring) in positive mode (see supplement). Standard curves were obtained in parallel using identical conditions. Data was analyzed using Analyst and Multiquant software [74].
analysis was performed with Analyst and Multiquant software packages [72, 74]. Samples for phospholipids were homogenized into 400µL of 10% methanol in water. A mix of PC 12/0/13/0, PE 12/0/13/0, PS 12/0/13/0, PI 12/0/13/0, PG 12/0/13/0, and PA 12/0/12/0 internal standard was added to 50µL of cell homogenate (Avanti Polar Lipids, Birmingham, AL, USA). Samples were extracted using a modified BUME method. The extracts were brought to dryness and reconstituted in Buffer A (59/40/1 isopropanol/hexane/10 mM ammonium acetate). The phospholipids were analyzed on a Waters Acquity UPLC interfaced with an AB Sciex 6500 QTrap mass spectrometer. A Phenomenex Silica 3uM 2.1 mm x 150 mm column was used for chromatographic separation using a step gradient from 100% buffer A to 100% buffer B (50/40/10 isopropanol/hexane/10 mM ammonium acetate) over 16 min. Phospholipid classes were separated by mass spectrometry using precursor ion (PI) and neutral loss (NL) scans in positive and negative ionization mode. Lipid classes were analyzed in Multiquant by selecting the TICs of the following scans for each class: PC, PI m/z 184 Da (+); PE, NLS 141 Da (+); PS, NLS 185 Da (+); PA, NLS 98 Da (+); PG, NLS 172 Da (+); and PI, PI m/z 241 Da (−). Lipid classes were quantified using whole cell extracts run in parallel (Avanti Polar Lipids) [74, 75]. Ceramide and sphingomyelin analysis was derived from phospholipid extraction and analysis.

Statistical analysis
GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses and graphical presentation. Statistical analyses of data were performed using the Student’s t test, and means were considered statistically different when p < 0.05. Lipids found to be statistically significantly different were uploaded to the metabolomics data analysis tool, MetaboAnalyst 5.0, for pathway analysis. All qPCR and immunoblot experiments were conducted in triplicate. Immunofluorescence data were analyzed with n = 10, RNA sequencing was analyzed using n = 3, initial lipidomic data were analyzed using n = 5, and lipidomic data following compound treatment were analyzed using n = 3. All data are presented as mean ± standard error of the mean.

Abbreviations
SCPx: Sterol carrier protein-x; SCP2: Sterol carrier protein 2; VLCFA: Very long-chain fatty acids; ACOX1: Acyl-CoA oxidase 1; LBP: L-bifunctional protein; ACAA1: 3-Ketoacyl-CoA thiolase; ACOX2: Acyl-CoA oxidase 2; DBP: D-bifunctional protein; AMACR: 2-Methylacyl-CoA racemase; PED: Peroxisomal enzyme deficiency; X-ALD: X-linked adrenoleukodystrophy; AMN: Adrenomyeloneuropathy; NHDF: Normal human dermal fibroblasts; NGS: Next-generation sequencing; BWA: Burrows-Wheeler Aligner; WGS: Whole-genome sequencing; VQSR: Variant quality score recalibration; HPO: Human phenotype ontology; BLAST: Basic Local Alignment Search Tool; PMP70: Peroxisomal membrane protein 70; CPT1A: Carnitine palmitoyltransferase 1; CYP7A1: Cholesterol 7α-hydroxylase; STAR: Steroidogenic acute regulatory protein; PG: Phosphatidylglycerol; PS: Phosphatidylserine; 4-OHT: 4-Hydroxytamoxifen; PD: Parkinson’s disease; GLUT1: Glucose transporter 1.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40246-022-00408-w.

Additional file 1: Table of Information for Antibodies. Description of antibodies including protein target, name of antibody, manufacturer and catalog number, and dilution used. Additional file 2: Table of Primers. Description of primers used, including primer name and sequence. Additional file 3: Complete fatty acid profile of NHDF and WESP cells following treatment. Measurement of various species of free fatty acids after treatment with 25 µM fenofibrate, 0.5 µM 4-Hydroxytamoxifen, or a combination of the two compounds for 24 hours. Data are shown as mean ± SEM (n=3), *p < 0.05; **p < 0.01; ***p < 0.001.

Acknowledgements
We are grateful to the USC Norris Comprehensive Cancer Center Molecular Genomics Core (CCSG grant (NCI grant #P30CA014089)) for their help with RNA sequencing. We would also like to acknowledge USC Libraries Bioinformatics Services for their help with RNA sequencing analysis. The software used for the analysis is funded by the USC Office of Research and the USC Libraries. We are also thankful to the UCSD Lipidomics Core for their help with lipidomic analyses. We would like to thank the staff at the Centre for Applied Genomics (TCAG) in Toronto and the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) for supporting this study. We also thank Dr. Jordan Lerner-Ellis at Mount Sinai Hospital, Sinai Health, for sample handling, analysis, and reporting of the genomic data.

Author contributions
MG contributed to methodology, formal analysis, investigation, data curation, writing the original draft, review and editing, and visualization. SE contributed to conceptualization, methodology, resources, review and editing, and funding acquisition. VP contributed to conceptualization, methodology, formal analysis, resources, review and editing, supervision, project administration, and funding acquisition. All authors read and approved the final manuscript.

Funding
This work was supported by the University of Southern California School of Pharmacy.

Availability of data and materials
The datasets supporting the conclusions of this article are included within this article and will be made available upon request or through the NCBI Gene Expression Omnibus (GEO) database: accession no. GSE199634 (token for reviewers: ijibuwmidzabdqn) and NCBI’s ClinVar: accession no.: VCWO01050589.2.

Declarations
Ethics approval and consent to participate
This individual was enrolled in the Adults with Undiagnosed Rare Disease genome sequencing research study approved by the Mount Sinai Hospital Research Ethics Board (#12–0222-E) [70]. These studies abide by the Declaration of Helsinki principles.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1895 Zonal Ave, Los Angeles, CA 90089, USA. 2 Department of Medicine, University of Toronto and Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada.
References

1. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Ann Rev Nutri. 2001;21:193–230.

2. Waterham HR, Ferdinandusse S, Wanders RJA. Human disorders of peroxisome metabolism and biogenesis. BBA-Mol Cell Res. 2016;1863:922–33.

3. Ferdinandusse S, Kostopoulos P, Denis S, Rusch H, Overmars H, Dillman U, Reith W, Haas D, Wanders RJA, Duran M, Marzinik M. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukenecrophalopathy with dystonia and motor neuropathy. Am J Hum Genet. 2006;78:1046–52.

4. Horvath R, Lewis-Smith D, Douroudis K, Duff J, Keogh M, Pyle A, Fletcher N, Chinnery PF. SCP2 mutations and neurodegeneration with brain iron accumulation. Neurology. 2015;85:1900–11.

5. Li NC, Fan JJ, Papadopoulos V. Sterol carrier protein-2, a nonspecific lipid transfer protein, in intracellular cholesterol trafficking in testicular Leydig cells. PLoS ONE. 2011;6:e194728.

6. Gallegos AM, Atshaves BP, Storey SM, McIntosh AL, Petrescu AD, Schroeder F. Sterol carrier protein-2 expression alters plasma membrane lipid distribution and cholesterol dynamics. Biochemistry. 2001;40:6493–506.

7. Puglielli L, Rogozi A, Greco AV, Santos MJ, Nervi F. Sterol carrier protein-2 is involved in cholesterol transfer from the endoplasmic-reticulum to the plasma membrane in human fibroblasts. J Biol Chem. 1995;270:18723–7.

8. Gadella TWJ, Wirtz KWA. The low-affinity lipid-binding site of the nonspecific lipid transfer protein: implications for its mode of action. Biochem Biophys Acta. 1991;1070:237–45.

9. Schroeder F, Myerspayne SC, Billheimer JT, Wood WG. Probing the ligand-binding sites of fatty acid and sterol carrier proteins: effects of ethanol. Biochemistry. 1995;34:11919–27.

10. Stolowich NJ, Frolov A, Atshaves B, Murphy EJ, Jolly CA, Billheimer JT, Scott AL, Schroeder F. The sterol carrier protein-2 fatty acid binding site: An NMR, circular dichroic, and fluorescence spectroscopic determination. Biochemistry. 1997;36:1719–29.

11. Frolov A, Miller K, Billheimer JT, Cho TH, Schroeder F. Lipid specificity and location of the sterol carrier protein-2 fatty acid-binding site: A fluorescence displacement and energy transfer study. Lipids. 1997;32:2101–9.

12. Gallegos AM, Atshaves BP, Storey SM, Starodub O, Petrescu AD, Huang H, McIntosh AL, Martin GG, Chao H, Kier AB, Schroeder F. Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. Prog Lipid Res. 2001;40:498–563.

13. Seedorf U, Raabe M, Ellinghaus P, Kannenberg F, Fobker M, Engel T, Assmann G, Börchers T, Vale-Santos JE, Wintzen AR, van Deutekom JC, Isles DE. Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis. J Med Genet. 1995;32:1046–52.

14. Dansen TB, Kops GJ, Denis S, Jelluma N, Wanders RJ, Bos JL, Burgering BM, Wirtz KW. Regulation of sterol carrier protein gene expression by the forkhead transcription factor FOXO3A. J Lipid Res. 2004;45:81–8.

15. Howald A, Hennig AF, Rolvin T, Rössler U, Steiner N, Kraus A, Böttger S, Zustin J, Geißler S, Oheim R, et al. Adult osteosclerotic metaphyseal dysplasia with progressive osteonecrosis of the jaws and abnormal bone resorption pattern due to a LRKK1 splice site mutation. J Bone Miner Res. 2020;35:1322–32.

16. Nishimura G, Kozlowski K. Osteosclerotic metaphyseal dysplasia. Pediatr Radiol. 1993;23:450–2.

17. Schulte EC, Ellwanger DC, Dihanich S, Manzioni C, Schormair B, Graf E, Eck S, Mollenhauer B, Haubenberger D, et al. Rare variants in LRKK1 and Parkinson’s disease. Neurogenetics. 2014;15:49–57.

18. Blomqvist M, Smeland MF, Lindgren J, Sikora P, Riise Stensland HM, Asin-Cayuela J. β-Mannosidosis caused by a novel homozygous intragenic inverted duplication in cold. In: Spring Harb Coll Case Stud. 2019;5:a003954.

19. Saffo Brozovska D, Varga L, Uhrova Meszarosova A, Slobozova Z, Skoplkova M, Soltsyova A, Ficek A, Jenck J, Lastuvkova J, Galashenkov D, Seeman P, Va B. Variant c.2158–2A>G in MANBA is an important and frequent cause of hereditary hearing loss and beta-mannosidosis among the Czech and Slovak Roma population- evidence for a new ethnic-specific variant. Orphanet J Rare Dis. 2020;15:222.

20. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG. Genetic disorders of renal electrolyte transport. N Engl J Med. 1999;340:1177–87.

21. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int. 1998;53:3–17.

22. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, Harding B, Bolino A, Devoto M, Goodyer P, et al. A common molecular basis for three inherited kidney stone diseases. Nature. 1996;379:445–9.

23. Boerman RH, Opoff RA, Links TP, van Eijk R, Sandkuijl LA, Elbaz A, Vale-Santos JE, Wintzen AR, van Deutekom JC, Isles DE. Mutation in DHP receptor alpha 1 subunit (CACLN1A3) in a Dutch family with hypokalemic periodic paralysis. J Med Genet. 1995;32:44–7.

24. Buruma OJ, Bots GT, Went LN. Familial hypokalaemic periodic paralysis: 50-year follow-up of a large family. Arch Neurol. 1985;42:28–31.

25. Miller RM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, Vale-Santos JE, Wintzen AR, van Deutekom JC, Isles DE. Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene encoding peroxisomal sterol carrier protein X (SCPx) cause leuke- ncephalopathy with dystonia and motor neuropathy. Am J Hum Genet. 2006;78:1046–52.

26. Nordgren M, Wang B, Apanasets O, Fransen M. Peroxisome degradation in mammals: mechanisms of action, recent advances, and perspectives. Front Physiol. 2013;4:145.

27. Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, De Bosscher K. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;39:760–802.

28. Ellinghaus P, Wolfrum C, Assmann G, Spener F, Seedorf U. Phytic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2/- sterol carrier protein x-deficient mice. J Biol Chem. 1999;274:766–72.

29. Chiang YJ. Bile acid regulation of sterol metabolism. J Lipid Res. 2009;50:1955–66.
